isabelobrien, Author at European Medical Journal - Page 17 of 29

The word spotlight on a blue background with the 'o' as a spotlight circle

Spotlight: May 2024

Catch up on May’s top pharma news in this monthly round-up. From the latest HCP insights on pharma companies to new investments, there’s plenty to discover.

3D human on blue background

Taking medical education into a new dimension

Learn about how 3D human technology offers pharmaceutical companies a fresh and exciting way to take medical education to new heights.

Picture of a pink illustrated brain on a mint green background

Elon Musk’s Neuralink seeks patients for clinical trial

Neuralink, Elon Musk’s brain chip company, is preparing for the first clinical trial of its implant technology.

a lighthouse shining on a group of people

Reaching healthcare professionals with the latest advances

The journey from approval to patient can be convoluted. How can pharma teams communicate the latest advances to busy healthcare professionals?

FDA nod for Roche and Amgen’s blood testing device

The FDA has granted Breakthrough Device Designation to Roche’s new blood test, developed in collaboration with Amgen, that measures key blood markers of inherited cardiovascular risk.

AZ’s Stefan Woxström on preparing healthcare systems for the future

Stefan Woxström, Senior Vice President Europe and Canada, AstraZeneca, talks about the need for future-proofing healthcare systems, incentivising innovation and reimbursement.

GSK pledges £45m to new antimicrobial resistance initiative

GSK has pledged £45m to the Fleming Initiative, a UK scheme to tackle antimicrobial resistance, led by Imperial College Healthcare NHS Trust and Imperial College London.

Pfizer and AstraZeneca to invest nearly $1bn in France

Pfizer and AstraZeneca have set their sights on France with major investments totalling nearly 1bn (USD) ahead of the country’s annual ‘Choose France’ business summit.

Spotlight: April 2024

Catch up on the top stories to come from the pharma industry over April, including new collaborations set to improve treatments for patients, the latest approvals and more.

Poor return on investment rates on the rise

The pharma industry’s ability to recoup costs on their drug development pipeline was in trouble, been is the downward spiral coming to an end? Read more.